Показатели, оцениваемые в фармакологических исследованиях ХОБЛ: от легочной функции до биомаркеров

1. Committee for Proprietary Medicinal Products. Points to consider on clinical investigation of medicinal products in the chronic treatment of patients with chronic obstructive pulmonary disease (COPD). London; 1999. CPMP / EWP / 562 / 98.

2. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932-946.

3. Edwards N. A framework for future trials: Guidelines on developing COPD drugs. Good Clin. Pract. J. 2004; 11: 1-5.

4. Jones P.W., Agusti A.G.N. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur. Respir. J. 2006; 27: 822-832.

5. Celli B.R., Calverley P.M., Rennard S.I. et al. Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir. Med. 2005; 99: 1546-1554.

6. ZuWallack R.L., Haggerty M.C., Jones P. Clinically meaningful outcomes in patients with chronic obstructive pulmonary disease. Am. J. Med. 2004; 117 (suppl. 12A): 49S-59S.

7. Miller M.R., Hankinson J., Brusasco V. et al. Standardisation of spirometry. Eur. Respir. J. 2005; 26: 319-338.

8. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am. Rev. Respir. Dis. 1991; 144: 1202-1218.

9. Quanjer P.H., Tammeling G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur. Respir. J. 1993; 16 (suppl. 16): 5-40.

10. Pellegrino R., Viegi G., Brusasco V. et al. Interpretative strategies for lung function tests. Eur. Respir. J. 2005; 26: 948-968.

11. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI / WHO Workshop Report 2005. www.goldcopd.com Date last accessed: November 2, 2007.

12. Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. J. A. M. A. 1994; 272: 1497-1505.

13. Anonymous. GSK's Ariflo gets US approvable letter for COPD. Scrip Wld Pharmaceut. News 2003; 21: Oct. 31, 2898.

14. Swanney M.P., Jensen R.L., Crichton D.A. et al. FEV6 is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction. Am. J. Respir. Crit. Care Med. 2000; 162: 917-919.

15. Hankinson J.L., Crapo R.O., Jensen R.L. Spirometric reference values for the 6-s FVC maneuver. Chest 2003; 124: 1805-1811.

16. Garcia-Rio F., Pino J.M., Dorgham A. et al. Spirometric reference equations for European females and males aged 65-85 yrs. Eur. Respir. J. 2004; 24: 397-405.

17. Vandevoorde J., Verbanck S., Schuermans D. et al. FEV1 / FEV6 and FEV6 as an alternative for FEV1 / FVC and FVC in the spirometric detection of airway obstruction and restriction. Chest 2005; 127: 1560-1564.

18. Akpinar-Elci M., Fedan K.B., Enright P.L. FEV6 as a surrogate for FVC in detecting airways obstruction and restriction in the workplace. Eur. Respir. J. 2006; 27: 374-377.

19. Pedersen O.F. FEV6: a shortcut in spirometry? Eur. Respir. J. 2006; 27: 245-247.

20. Vandevoorde J., Verbanck S., Schuermans D. et al. Obstructive and restrictive spirometric patterns: fixed cut-offs for FEV1 / FEV6 and FEV6. Eur. Respir. J. 2006; 27: 378-383.

21. Bang K.M., Gergen P.J., Kramer R., Cohen B. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest 1993; 103: 536-540.

22. Neas L.M., Schwartz J. Pulmonary function levels as predictors of mortality in a national sample of US adults. Am. J. Epidemiol. 1998; 147: 1011-1018.

23. Knuiman M.W., James A.L., Divitini M.L. et al. Lung function, respiratory symptoms, and mortality: results from the Busselton Health Study. Ann. Epidemiol. 1999; 9: 297-306.

24. Schunemann H.J., Dorn J., Grant B.J. et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000; 118: 656-664.

25. Stavem K., Aaser E., Sandvik L. et al. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. Eur. Respir. J. 2005; 25: 618-625.

26. Wolkove N., Dajczman E., Colacone A., Kreisman H. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest 1989; 96: 1247-1251.

27. Hay J.G., Stone P., Carter J. et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur. Respir. J. 1992; 5: 659-664.

28. Bauerle O., Chrusch C.A., Younes M. Mechanisms by which COPD affects exercise tolerance. Am. J. Respir. Crit. Care Med. 1998; 157: 57-68.

29. O'Donnell D.E., Lam M., Webb K.A. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 542-549.

30. Ferrer M., Alonso J., Prieto L. et al. Validity and reliability of the St George's Respiratory Questionnaire after adaptation to a different language and culture: the Spanish example. Eur. Respir. J. 1996; 9: 1160-1166.

31. Hajiro T., Nishimura K., Tsukino M. et al. Comparison of discriminative properties among disease-specific questionnaires for measuring healthrelated quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 785-790.

32. Pellegrino R., Rodarte J.R., Brusasco V. Assessing the reversibility of airway obstruction. Chest 1998; 114: 1607-1612.

33. Calverley P.M., Burge P.S., Spencer S. et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659-664.

34. TheNational Emphysema Treatment Trial Research Group. Rationale and design of The National Emphysema Treatment Trial: a prospective randomized trial of lung volume reduction surgery. Chest 1999; 116: 1750-1761.

35. Seemungal T.A., Donaldson G.C., Bhowmik A. et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1608-1613.

36. Aaron S.D., Vandemheen K.L., Clinch J.J. et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002; 121: 688-696.

37. Niewoehner D.E., Collins D., Erbland M.L. Relation of FEV1 to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. Am. J. Respir. Crit. Care Med. 2000; 161: 1201-1205.

38. Parker C.M., Voduc N., Aaron S.D. et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur. Respir. J. 2005; 26: 420-428.

39. Cerveri I., Pellegrino R., Dore R., et al. Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J. Appl. Physiol. 2000; 88: 1989-1995.

40. van Schayck C.P., Loozen J.M., Wagena E. et al. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. Br. Med. J. 2002; 324: 1370.

41. Miller M.R., Crapo R., Hankinson J. et al. General considerations for lung function testing. Eur. Respir. J. 2005; 26: 153-161.

42. Wanger J., Clausen J.L., Coates A. et al. Standardisation of the measurement of lung volumes. Eur. Respir. J. 2005; 26: 511-522.

43. Stocks J., Quanjer P.H. Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung Volume Measurements. Official Statement of The European Respiratory Society. Eur. Respir. J. 1995; 8: 492-506.

44. Hankinson J.L., Stocks J., Peslin R. Reproducibility of lung volume measurements. Eur. Respir. J. 1998; 11: 787-790.

45. O'Donnell D.E., Revill S.M., Webb K.A. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 770-777.

46. Boni E., Corda L., Franchini D. et al. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest. Thorax 2002; 57: 528-532.

47. O'Donnell D.E., Webb K.A. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am. Rev. Respir. Dis. 1993; 148: 1351-1357.

48. O'Donnell D.E., Webb K.A., Bertley J.C. et al. Mechanisms of relief of exertional breathlessness following unilateral bullectomy and lung volume reduction surgery in emphysema. Chest 1996; 110: 18-27.

49. O'Donnell D.E., Fluge T., Gerken F., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23: 832-840.

50. O'Donnell D.E., Voduc N., Fitzpatrick M., Webb K.A. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur. Respir. J. 2004; 24: 86-94.

51. Diaz O., Villafranca C., Ghezzo H. et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur. Respir. J. 2000; 16: 269-275.

52. Marin J.M., Carrizo S.J., Gascon M. et al. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1395-1399.

53. Newton M.F., O'Donnell D.E., Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121: 1042-1050.

54. Murciano D., Ferretti A., Boczkowski J. et al. Flow limitation and dynamic hyperinflation during exercise in COPD patients after single lung transplantation. Chest 2000; 118: 1248-1254.

55. Casanova C., Cote C., de Torres J.P. et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171: 591-597.

56. Ingenito E.P., Loring S.H., Moy M.L. et al. Physiological characterization of variability in response to lung volume reduction surgery. J. Appl. Physiol. 2003; 94: 20-30.

57. Tantucci C., Duguet A., Similowski T. et al. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur. Respir. J. 1998; 12: 799-804.

58. Maltais F., Hamilton A., Marciniuk D. et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128: 1168-1178.

59. O'Donnell D.E. Is sustained pharmacologic lung volume reduction now possible in COPD? Chest 2006; 129: 501-503.

60. Celli B., ZuWallack R., Wang S., Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743-1748.

61. van Noord J.A., Aumann J.L., Janssens E. et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509-517.

62. Stevenson N.J., Walker P.P., Costello R.W., Calverley P.M. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 172: 1510-1516.

63. Duranti R., Filippelli M., Bianchi R. et al. Inspiratory capacity and decrease in lung hyperinflation with albuterol in COPD. Chest 2002; 122: 2009-2014.

64. Dolmage T.E., Goldstein R.S. Repeatability of inspiratory capacity during incremental exercise in patients with severe COPD. Chest 2002; 121: 708-714.

65. Yan S., Kaminski D., Sliwinski P. Reliability of inspiratory capacity for estimating end-expiratory lung volume changes during exercise in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1997; 156: 55-59.

66. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique - 1995 update. Am. J. Respir. Crit. Care Med. 1995; 152: 2185-2198.

67. Cramer D. Standardization of the measurement of transfer factor. Eur. Respir. J. 1993; 6: 1577-1578.

68. Macintyre N., Crapo R.O., Viegi G. et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur. Respir. J. 2005; 26: 720-735.

69. Paoletti P., Viegi G., Pistelli G. et al. Reference equations for the single-breath diffusing capacity. A cross-sectional analysis and effect of body size and age. Am. Rev. Respir. Dis. 1985; 132: 806-813.

70. Knudson R.J., Kaltenborn W.T., Knudson D.E., Burrows B. The single-breath carbon monoxide diffusing capacity. Reference equations derived from a healthy nonsmoking population and effects of hematocrit. Am. Rev. Respir. Dis. 1987; 135: 805-811.

71. Roca J., Rodriguez-Roisin R., Cobo E. et al. Single-breath carbon monoxide diffusing capacity prediction equations from a Mediterranean population. Am. Rev. Respir. Dis. 1990; 141: 1026-1032.

72. Cerveri I., Dore R., Corsico A. et al. Assessment of emphysema in COPD: a functional and radiologic study. Chest 2004; 125: 1714-1718.

73. Goldberg R., Hillberg R., Reinecker L., Goldstein R. Evaluation of patients with severe pulmonary disease before and after pulmonary rehabilitation. Disabil. and Rehabil. 2004; 26: 641-648.

74. Trow T.K. Lung-volume reduction surgery for severe emphysema: appraisal of its current status. Curr. Opin. Pulm. Med. 2004; 10: 128-132.

75. Meyers B.F., Yusen R.D., Guthrie T.J. et al. Results of lung volume reduction surgery in patients meeting a national emphysema treatment trial high-risk criterion. J. Thorac. Cardiovasc. Surg. 2004; 127: 829-835.

76. Wanger J., Irvin C. Comparability of pulmonary function results from 13 laboratories in a metropolitan area. Respir. Care 1991; 36: 1375-1382.

77. Gaensler E.A., Smith A.A. Attachment for automated single breath diffusing capacity measurement. Chest 1973; 63: 136-145.

78. Punjabi N.M., Shade D., Patel A.M., Wise R.A. Measurement variability in single-breath diffusing capacity of the lung. Chest 2003; 123: 1082-1089.

79. Hathaway E.H., Tashkin D.P., Simmons M.S. Intraindividual variability in serial measurements of DL,CO and alveolar volume over one year in eight healthy subjects using three independent measuring systems. Am. Rev. Respir. Dis. 1989; 140: 1818-1822.

80. Bolliger C.T., Koegelenberg C.F., Kendal R. Preoperative assessment for lung cancer surgery. Curr. Opin. Pulm. Med. 2005; 11: 301-306.

81. Schluchter M.D., Stoller J.K., Barker A.F. et al. Feasibility of a clinical trial of augmentation therapy for a1-antitrypsin deficiency. The a1-Antitrypsin Deficiency Registry Study Group. Am. J. Respir. Crit. Care Med. 2000; 161: 796-801.

82. Stoller J.K., Snider G.L., Brantly M.L. et al. American Thoracic Society / European Respiratory Society Statement: Standards for the diagnosis and management of individuals with a1-antitrypsin deficiency. Pneumologie 2005; 59: 36-68.

83. Eaton T., Rudkin S., Garrett J.E. The clinical utility of arterialized earlobe capillary blood in the assessment of patients for long-term oxygen therapy. Respir. Med. 2001; 95: 655-660.

84. Fajac I., Texereau J., Rivoal V. et al. Blood gas measurement during exercise: a comparative study between arterialized earlobe sampling and direct arterial puncture in adults. Eur. Respir. J. 1998; 11: 712-715.

85. Williams A.J. ABC of oxygen: assessing and interpreting arterial blood gases and acid-base balance. Br. Med. J. 1998; 317: 1213-1216.

86. Raff H. The significance of the blood gas analyzer. J. Appl. Physiol. 2004; 97: 1597-1598.

87. Severinghaus J.W. First electrodes for blood PO2 and PCO2 determination. J. Appl. Physiol. 2004; 97: 1599-1600.

88. Aoyagi T. Pulse oximetry: its invention, theory, and future. J. Anesth. 2003; 17: 259-266.

89. Jubran A. Pulse oximetry. Intensive Care Med. 2004; 30: 2017-2020.

90. Sinex J.E. Pulse oximetry: principles and limitations. Am. J. Emerg. Med. 1999; 17: 59-67.

91. Welch J. Pulse oximeters. Biomed Instrum Technol 2005; 39: 125-130.

92. Cerveri I., Zoia M.C., Fanfulla F. et al. Reference values of arterial oxygen tension in the middle-aged and elderly. Am. J. Respir. Crit. Care Med. 1995; 152: 934-941.

93. Hardie J.A., Vollmer W.M., Buist A.S. et al. Reference values for arterial blood gases in the elderly. Chest 2004; 125: 2053-2060.

94. Soler-Cataluña J.J., Martínez-García M.A., Román Sánchez P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931.

95. Gunen H., Hacievliyagil S.S., Kosar F. et al. Factors affecting survival of hospitalised patients with COPD. Eur. Respir. J. 2005; 26: 234-241.

96. Gay P.C. Chronic obstructive pulmonary disease and sleep. Respir. Care 2004; 49: 39-51.

97. Littner M.R. Portable monitoring in the diagnosis of the obstructive sleep apnea syndrome. Semin. Respir. Crit. Care Med. 2005; 26: 56-67.

98. Datta D., Vitale A., Lahiri B., ZuWallack R. An evaluation of nebulized levalbuterol in stable COPD. Chest 2003; 124: 844-849.

99. Sans-Torres J., Domingo C., Moron A. et al. Long-term effects of almitrine bismesylate in COPD patients with chronic hypoxaemia. Respir. Med. 2003; 97: 599-605.

100. Cazzola M., Santus P., Matera M.G. et al. A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD. Respir. Med. 2003; 97: 458-462.

101. Cazzola M., Santus P., di Marco F. et al. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. Respir. Med. 2003; 97: 453-457.

102. Jaen Díaz J.I., de Castro M.C., Cordero G.B. et al. Effectiveness of treatment with tiotropium in patients who suffer from COPD. Med. Clin. (Barc.) 2005; 124: 1-3.

103. Soto F.J., Varkey B. Evidence-based approach to acute exacerbations of COPD. Curr. Opin. Pulm. Med. 2003; 9: 117-124.

104. Higgins D. Pulse oximetry. Nurs. Times 2005; 101: 34-35.

105. Lawrence J.P. Advances and new insights in monitoring. Thorac. Surg. Clin. 2005; 15: 55-70.

106. Hildick-Smith D.J., Lowe M.D., Walsh J.T. et al. Coronary angiography from the radial artery - experience, complications and limitations. Int. J. Cardiol. 1998; 64: 231-239.

107. Fabbri L.M., Hurd S.S. Global Strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur. Respir. J. 2003; 22: 1-2.

108. Arnold R., Ranchor A.V., Koeter G.H. et al. Consequences of chronic obstructive pulmonary disease and chronic heart failure: the relationship between objective and subjective health. Soc. Sci. Med. 2005; 61: 2144-2154.

109. Jones P., Lareau S., Mahler D.A. Measuring the effects of COPD on the patient. Respir. Med. 2005; 99 (suppl. 2): S11-S18.

110. Hickey A.M., Bury G., O'Boyle C.A. et al. A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV / AIDS. Br. Med. J. 1996; 313: 29-33.

111. American Thoracic Society. Quality of Life Resource. www.atsqol.org Date last accessed: October 25, 2007.

112. Ware J.E. Jr., Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQoLA) project. J. Clin. Epidemiol. 1998; 51: 903-912.

113. Bergner M. The sickness impact profile. In: Walker S.R., ed. Quality of life: Assessment and application. Boston: M. T. P.; 1987. 79-94.

114. Hunt S.M., McEwen J. The development of a subjective health indicator. Soc. Hlth Illn. 1980; 2: 231-246.

115. Guyatt G.H., Berman L.B., Townsend M. et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: 773-778.

116. Schunemann H.J., Goldstein R., Mador M.J. et al. A randomised trial to evaluate the self-administered standardized chronic respiratory questionnaire. Eur. Respir. J. 2005; 25: 31-40.

117. Puhan M.A., Behnke M., Frey M. et al. Self-administration and interviewer-administration of the German Chronic Respiratory Questionnaire: instrument development and assessment of validity and reliability in two randomized studies. Hlth Qual. Life Outcomes 2004; 2: 1.

118. Wyrwich K.W., Tierney W.M., Wolinsky F.D. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J. Clin. Epidemiol. 1999; 52: 861-873.

119. Jones P.W., Quirk F.H., Baveystock C.M., Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am. Rev. Respir. Dis. 1992; 145: 1321-1327.

120. Wilson C.B., Jones P.W., O'Leary C.J. et al. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am. J. Respir. Crit. Care Med. 1997; 156: 536-541.

121. Maille A.R., Koning C.J., Zwinderman A.H. et al. The development of the ''Quality-of-life for Respiratory Illness Questionnaire (QoL-RIQ)'': a disease-specific quality-of-life questionnaire for patients with mild to moderate chronic nonspecific lung disease. Respir. Med. 1997; 91: 297-309.

122. Jacobs J.E., Maille A.R., Akkermans R.P. et al. Assessing the quality of life of adults with chronic respiratory diseases in routine primary care: construction and first validation of the 10-Item Respiratory Illness Questionnaire-Monitoring 10 (RIQMON10). Qual. Life Res. 2004; 13: 1117-1127.

123. Barley E.A., Quirk F.H., Jones P.W. Asthma health status measurement in clinical practice: validity of a new short and simple instrument. Respir. Med. 1998; 92: 1207-1214.

124. Hajiro T., Nishimura K., Jones P.W. et al. A novel, short, and simple questionnaire to measure health-related quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159: 1874-1878.

125. Alemayehu B., Aubert R.E., Feifer R.A., Paul L.D. Comparative analysis of two quality-of-life instruments for patients with chronic obstructive pulmonary disease. Value Hlth 2002; 5: 436-441.

126. Hyland M.E., Bott J., Singh S., Kenyon C.A. Domains, constructs and the development of the breathing problems questionnaire. Qual. Life Res. 1994; 3: 245-256.

127. Hyland M.E., Singh S.J., Sodergren S.C., Morgan M.P. Development of a shortened version of the Breathing Problems Questionnaire suitable for use in a pulmonary rehabilitation clinic: a purpose-specific, disease-specific questionnaire. Qual. Life Res. 1998; 7: 227-233.

128. Carone M., Bertolotti G., Anchisi F. et al. Analysis of factors that characterize health impairment in patients with chronic respiratory failure. Quality of Life in Chronic Respiratory Failure Group. Eur. Respir. J. 1999; 13: 1293-1300.

129. van der Molen T., Willemse B.W., Schokker S. et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Hlth Qual. Life Outcomes 2003; 1: 13.

130. Lareau S.C., Meek P.M., Roos P.J. Development and testing of the modified version of the pulmonary functional status and dyspnoea questionnaire (PFSDQ-M). Heart Lung 1998; 27: 159-168.

131. Weaver T.E., Narsavage G.L., Guilfoyle M.J. The development and psychometric evaluation of the Pulmonary Functional Status Scale: an instrument to assess functional status in pulmonary disease. J. Cardiopulm. Rehabil. 1998; 18: 105-111.

132. Nouri F.M., Lincoln N.B. An extended activities of daily living scale for stroke patients. Clin. Rehabil. 1987; 1: 301-305.

133. Okubadejo A.A., O'Shea L., Jones P.W., Wedzicha J.A. Home assessment of activities of daily living in patients with severe chronic obstructive pulmonary disease on longterm oxygen therapy. Eur. Respir. J. 1997; 10: 1572-1575.

134. Garrod R., Bestall J.C., Paul E.A. et al. Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL). Respir. Med. 2000; 94: 589-596.

135. Schunemann H.J., Goldstein R., Mador M.J. et al. Do clinical marker states improve responsiveness and construct validity of the standard gamble and feeling thermometer: a randomized multi-center trial in patients with chronic respiratory disease. Qual. Life Res. 2006; 15: 1-14.

136. Schunemann H.J., Griffith L., Stubbing D. et al. A clinical trial to evaluate the measurement properties of 2 direct preference instruments administered with and without hypothetical marker states. Med. Decis Making 2003; 23: 140-149.

137. Schunemann H.J., Griffith L., Jaeschke R. et al. Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction. J. Clin. Epidemiol. 2003; 56: 1170-1176.

138. Puhan M.A., Guyatt G.H., Montori V.M. et al. The standard gamble demonstrated lower reliability than the feeling thermometer. J. Clin. Epidemiol. 2005; 58: 458-465.

139. Kaplan R.M., Atkins C.J., Timms R. Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease. J. Chron. Dis. 1984; 37: 85-95.

140. EuroQol Group. EQ-5D. http://www.euroqol.org. Date last accessed: October 25, 2007.

141. Mahler D.A. Measurement of dyspnea: clinical ratings. In: Mahler D.A., ed. Dyspnea: Mechanisms, measurement and management. 2nd ed. New York: Taylor & Francis Inc.; 2005. 147-164.

142. Fletcher C.M., Elmes P.C., Fairbairn A.S., Wood C.H. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br. Med. J. 1959; 5147: 257-266.

143. Mahler D.A., Weinberg D.H., Wells C.K., Feinstein A.R. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.

144. Bestall J.C., Paul E.A., Garrod R. et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-586.

145. Hajiro T., Nishimura K., Tsukino M. et al. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 158: 1185-1189.

146. Ries A.L., Kaplan R.M., Blumberg E. Use of factor analysis to consolidate multiple outcome measures in chronic obstructive pulmonary disease. J. Clin. Epidemiol. 1991; 44: 497-503.

147. Mahler D.A., Harver A. A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1992; 145: 467-470.

148. Mahler D.A., Ward J., Fierro-Carrion G. et al. Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. J. COPD 2004; 1: 1-8.

149. Witek T.J. Jr., Mahler D.A. Meaningful effect size and patterns of response of the transition dyspnea index. J. Clin. Epidemiol. 2003; 56: 248-255.

150. Witek T.J. Jr., Mahler D.A. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur. Respir. J. 2003; 21: 267-272.

151. Mahler D.A., Tomlinson D., Olmstead E.M. et al. Changes in dyspnea, health status, and lung function in chronic airway disease. Am. J. Respir. Crit. Care Med. 1995; 151: 61-65.

152. Casaburi R., Mahler D.A., Jones P.W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.

153. Mahler DA. Dyspnea. In: Celli BR, ed. Pharmacotherapy of COPD. New York: Marcel Dekker Inc.; 2003. 145-158.

154. Brusasco V., Hodder R., Miravitlles M. et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.

155. ZuWallack R.L., Mahler D.A., Reilly D. et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661-1670.

156. Vincken W., van Noord J.A., Greefhorst A.P. et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209-216.

157. Donohue J.F., Kalberg C., Emmett A. et al. A short-term comparison of fluticasone propionate / salmeterol with ipratropium bromide / albuterol for the treatment of COPD. Treat Respir. Med. 2004; 3: 173-181.

158. Donohue J.F., van Noord J.A., Bateman E.D. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.

159. Hanania N.A., Darken P., Horstman D. et al. The efficacy and safety of fluticasone propionate (250 mg) / salmeterol (50 mg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124: 834-843.

160. Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166: 1084-1091.

161. Aaron S.D., Vandemheen K.L., Hebert P. et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N. Engl. J. Med. 2003; 348: 2618-2625.

162. Guyatt G.H., Townsend M., Pugsley S.O. et al. Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. Am. Rev. Respir. Dis. 1987; 135: 1069-1074.

163. Mahler D.A., Donohue J.F., Barbee R.A. et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965.

164. Rennard S.I., Anderson W., ZuWallack R. et al. Use of a long-acting inhaled b2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1087-1092.

165. Rutten-van Mölken M., Roos B., van Noord J.A. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax 1999; 54: 995-1003.

166. Borg G.A. Psychophysical bases of perceived exertion. Med. Sci Sports Exerc. 1982; 14: 377-381.

167. Mahler D.A., Mejia-Alfaro R., Ward J., Baird J.C. Continuous measurement of breathlessness during exercise: validity, reliability, and responsiveness. J. Appl. Physiol. 2001; 90: 2188-2196.

168. Fierro-Carrion G., Mahler D.A., Ward J., Baird J.C. Comparison of continuous and discrete measurements of dyspnea during exercise in patients with COPD and normal subjects. Chest 2004; 125: 77-84.

169. Mahler D.A., Fierro-Carrion G., Mejia-Alfaro R. et al. Responsiveness of continuous ratings of dyspnea during exercise in patients with COPD. Med. Sci. Sports Exerc. 2005; 37: 529-535.

170. Mahler D.A. Clinical measurement of dyspnea. In: Mahler D.A., ed. Dyspnea. Lung Biology in Health and Disease. New York, Marcel Dekker Inc.; 1998. 149-198.

171. Hamilton A.L., Killian K.J., Summers E., Jones N.L. Symptom intensity and subjective limitation to exercise in patients with cardiorespiratory disorders. Chest 1996; 110: 1255-1263.

172. Teramoto S., Fukuchi Y., Orimo H. Effects of inhaled anticholinergic drug on dyspnea and gas exchange during exercise in patients with chronic obstructive pulmonary disease. Chest 1993; 103: 1774-1782.

173. Ayers M.L., Mejia R., Ward J. et al. Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Eur. Respir. J. 2001; 17: 1132-1137.

174. Jones P.W. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56: 880-887.

175. Jones P.W., Quirk F.H., Baveystock C.M. Why quality of life measures should be used in the treatment of patients with respiratory illness. Monaldi Arch. Chest Dis. 1994; 49: 79-82.

176. Campbell M., Eliraz A., Johansson G. et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir. Med. 2005; 99: 1511-1520.

177. Franciosi L.G., Page C.P., Celli B.R. et al. Markers of disease severity in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2006; 19: 189-199.

178. Seemungal T.A., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1418-1422.

179. Miravitlles M., Ferrer M., Pont A. et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59: 387-395.

180. Doll H., Miravitlles M. Health-related QoL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics 2005; 23: 345-363.

181. Schmier J.K., Halpern M.T., Higashi M.K., Bakst A. The quality of life impact of acute exacerbations of chronic bronchitis (AECB): a literature review. Qual. Life Res. 2005; 14: 329-347.

182. Burrows B., Earle R.H. Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. N. Engl. J. Med. 1969; 280: 397-404.

183. Hurst J.R., Donaldson G.C., Perera W.R. et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174: 867-874.

184. Pauwels R., Calverley P., Buist A.S. et al. COPD exacerbations: the importance of a standard definition. Respir. Med. 2004; 98: 99-107.

185. Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196-204.

186. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117 (suppl. 2): 398S-401S.

187. Decramer M., Rutten-van M#ölken M., Dekhuijzen P.N. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365: 1552-1560.

188. Fabbri L., Beghe B., Caramori G. et al. Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease. Thorax 1998; 53: 803-808.

189. Wilkinson T.M., Donaldson G.C., Hurst J.R. et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 169: 1298-1303.

190. Burge P.S., Calverley P.M., Jones P.W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297-1303.

191. Calverley P.M., Boonsawat W., Cseke Z. et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22: 912-919.

192. Kessler R., Stahl E., Vogelmeier C. et al. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest 2006; 130: 133-142.

193. Allegra L., Grassi C., Grossi E. et al. Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico. [Role of antibiotics in the treatment of acute exacerbations of chronic bronchitis: results from an Italian multicentre trial.] Ital J. Chest Dis. 1991; 45: 138-148.

194. Donaldson G.C., Seemungal T.A., Patel I.S. et al. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur. Respir. J. 2003; 22: 931-936.

195. Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide / formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74-81.

196. Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. Eur. Respir. J. 2004; 24: 206-210.

197. Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.

198. Jones P.W., Willits L.R., Burge P.S., Calverley P.M. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur. Respir. J. 2003; 21: 68-73.

199. Gompertz S., Bayley D.L., Hill S.L., Stockley R.A. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001; 56: 36-41.

200. Spencer S., Calverley P.M., Burge P.S., Jones P.W. Impact of preventing exacerbations on deterioration of health status in COPD. Eur. Respir. J. 2004; 23: 698-702.

201. Miravitlles M., Murio C., Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. Eur. Respir. J. 2001; 17: 928-933.

202. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 173: 842-846.

203. Miravitlles M., Murio C., Guerrero T., Gisbert R. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449-1455.

204. Garcia-Aymerich J., Monso E., Marrades R.M. et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. Am. J. Respir. Crit. Care Med. 2001; 164: 1002-1007.

205. Miravitlles M., Guerrero T., Mayordomo C. et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 2000; 67: 495-501.

206. Antonelli I., Fuso L., De Rosa M. et al. Comorbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 1997; 10: 2794-2800.

207. Dowson L.J., Newall C., Guest P.J. et al. Exercise capacity predicts health status in a1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 2001; 163: 936-941.

208. Clinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies. ERS Task Force on Standardization of Clinical Exercise Testing. European Respiratory Society. Eur. Respir. J. 1997; 10: 2662-2689. 209. ATS / ACCP Statement on cardiopulmonary exercise testing. Am. J. Respir. Crit. Care Med. 2003; 167: 211-277.

209. Saey D., Michaud A., Couillard A. et al. Contractile fatigue, muscle morphometry, and blood lactate in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171: 1109-1115.

210. Bowen J.B., Votto J.J., Thrall R.S. et al. Functional status and survival following pulmonary rehabilitation. Chest 2000; 118: 697-703.

211. Oga T., Nishimura K., Tsukino M. et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am. J. Respir. Crit. Care Med. 2003; 167: 544-549.

212. Oga T., Nishimura K., Tsukino M. et al. The effects of oxitropiumbromide on exercise performance in patients with stable chronic obstructive pulmonary disease. A comparison of three different exercise tests. Am. J. Respir. Crit. Care Med. 2000; 161: 1897-1901.

213. Palange P., Crimi E., Pellegrino R., Brusasco V. Supplemental oxygen and heliox: ''new'' tools for exercise training in chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. 2005; 11: 145-148.

214. Butland R.J., Pang J., Gross E.R. et al. Two-, six-, and 12-minute walking tests in respiratory disease. Br. Med. J. (Clin. Res. Ed.) 1982; 284: 1607-1608.

215. Palange P., Forte S., Onorati P. et al. Ventilatory and metabolic adaptations to walking and cycling in patients with COPD. J. Appl. Physiol. 2000; 88: 1715-1720.

216. Man W.D., Soliman M.G., Gearing J. et al. Symptoms and quadriceps fatigability after walking and cycling in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 168: 562-567.

217. Fishman A., Martinez F., Naunheim K. et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N. Engl. J. Med. 2003; 348: 2059-2073.

218. Sue D.Y., Wasserman K., Moricca R.B., Casaburi R. Metabolic acidosis during exercise in patients with chronic obstructive pulmonary disease. Use of the Vslope method for anaerobic threshold determination. Chest 1988; 94: 931-938.

219. Aliverti A., Stevenson N., Dellaca R.L. et al. Regional chest wall volumes during exercise in chronic obstructive pulmonary disease. Thorax 2004; 59: 210-216.

220. Myers J., Prakash M., Froelicher V. et al. Exercise capacity and mortality among men referred for exercise testing. N. Engl. J. Med. 2002; 346: 793-801.

221. Pellegrino R., Villosio C., Milanese U. et al. Breathing during exercise in subjects with mild-to-moderate airflow obstruction: effects of physical training. J. Appl. Physiol. 1999; 87: 1697-1704.

222. Casaburi R., Porszasz J., Burns M.R. et al. Physiologic benefits of exercise training in rehabilitation of patients with severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1997; 155: 1541-1551.

223. Martinez F.J., de Oca M.M., Whyte R.I. et al. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am. J. Respir. Crit. Care Med. 1997; 155: 1984-1990.

224. Somfay A., Porszasz J., Lee S.M., Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur. Respir. J. 2001; 18: 77-84.

225. O'Donnell D.E., D'Arsigny C., Webb K.A. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 892-898.

226. Palange P., Valli G., Onorati P. et al. Effect of heliox on lung dynamic hyperinflation, dyspnea, and exercise endurance capacity in COPD patients. J. Appl. Physiol. 2004; 97: 1637-1642.

227. McGavin C.R., Gupta S.P., McHardy G.J. Twelve-minute walking test for assessing disability in chronic bronchitis. Br. Med. J. 1976; 1: 822-823.

228. Morgan A.D., Peck D.F., Buchanan D.R., McHardy G.J. Effect of attitudes and beliefs on exercise tolerance in chronic bronchitis. Br. Med. J. (Clin. Res. Ed.) 1983; 286: 171-173.

229. Sciurba F., Criner G.J., Lee S.M. et al. Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am. J. Respir. Crit. Care Med. 2003; 167: 1522-1527.

230. Guyatt G.H., Sullivan M.J., Thompson P.J. et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can. Med. Assoc. J. 1985; 132: 919-923.

231. Knox A.J., Morrison J.F., Muers M.F. Reproducibility of walking test results in chronic obstructive airways disease. Thorax 1988; 43: 388-392.

232. Gerardi D.A., Lovett L., Benoit-Connors M.L. et al. Variables related to increased mortality following outpatient pulmonary rehabilitation. Eur. Respir. J. 1996; 9: 431-435.

233. Geddes D., Davies M., Koyama H. et al. Effect of lungvolume-reduction surgery in patients with severe emphysema. N. Engl. J. Med. 2000; 343: 239-245.

234. Young J., Fry-Smith A., Hyde C. Lung volume reduction surgery (LVRS) for chronic obstructive pulmonary disease (COPD) with underlying severe emphysema. Thorax 1999; 54: 779-789.

235. Griffiths T.L., Burr M.L., Campbell I.A. et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000; 355: 362-368.

236. Leach R.M., Davidson A.C., Chinn S. et al. Portable liquid oxygen and exercise ability in severe respiratory disability. Thorax 1992; 47: 781-789.

237. Corris P.A., Neville E., Nariman S., Gibson G.J. Dose-response study of inhaled salbutamol powder in chronic airflow obstruction. Thorax 1983; 38: 292-296.

238. Onorati P., Antonucci R., Valli G. et al. Non-invasive evaluation of gas exchange during a shuttle walking test versus a 6-min walking test to assess exercise tolerance in COPD patients. Eur. J. Appl. Physiol. 2003; 89: 331-336.

239. Singh S.J., Morgan M.D., Scott S. et al. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992; 47: 1019-1024.

240. Revill S.M., Morgan M.D., Singh S.J. et al. The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax 1999; 54: 213-222.

241. Man W.D., Polkey M.I., Donaldson N. et al.Community pulmonary rehabilitation after hospitalization for acute exacerbations of chronic obstructive pulmonary disease: a randomised controlled study. Br. Med. J. 2004; 329: 1209.

242. Fuld J.P., Kilduff L.P., Neder J.A. et al. Creatine supplementation during pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax 2005; 60: 531-537.

243. Steiner M.C., Barton R.L., Singh S.J., Morgan M.D. Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease: a randomised controlled trial. Thorax 2003; 58: 745-751.

244. Eiser N., Willsher D., Dore C.J. Reliability, repeatability and sensitivity to change of externally and self-paced walking tests in COPD patients. Respir. Med. 2003; 97: 407-414.

245. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann. Intern. Med. 1980; 93: 391-398.

246. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681-686.

247. Sin D.D., Wu L., Anderson J.A. et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-997.

248. Hansell A.L., Walk J.A., Soriano J.B. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur. Respir. J. 2003; 22: 809-814.

249. Camilli A.E., Robbins D.R., Lebowitz MD. Death certificate reporting of confirmed airways obstructive disease. Am. J. Epidemiol. 1991; 133: 795-800.

250. Anthonisen N.R., Skeans M.A., Wise R.A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233-239.

251. Sin D.D., Man S.F. Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can. J. Physiol. Pharmacol. 2005; 83: 8-13.

252. Solomon S.D., Wang D., Finn P. et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004; 110: 2180-2183.

253. Curb J.D., McTiernan A., Heckbert S.R. et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann. Epidemiol. 2003; 13 (suppl. 9): S122-S128.

254. Remington R.D. Who should code cause of death in a clinical trial? Control Clin. Trials 1984; 5: 241-244.

255. Walter S.D., Cook D.J., Guyatt G.H. et al. Outcome assessment for clinical trials: how many adjudicators do we need? Canadian Lung Oncology Group. Control Clin. Trials 1997; 18: 27-42.

256. Anthonisen N.R., Wright E.C., Hodgkin J.E. Prognosis in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1986; 133: 14-20.

257. Anthonisen N.R., Connett J.E., Enright P..L, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am. J. Respir. Crit. Care Med. 2002; 166: 333-339.

258. Celli B.R., Cote C.G., Marin J.M. et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 1005-1012.

259. Hansen E.F., Phanareth K., Laursen L.C. et al. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159: 1267-1271.

260. Landbo C., Prescott E., Lange P. et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 1856-1861.

261. Mannino D.M., Buist A.S., Petty T.L. et al.Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003; 58: 388-393.

262. Nishimura K., Izumi T., Tsukino M., Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434-1440.

263. Oga T., Nishimura K., Tsukino M. et al. Health status measured with the CRQ does not predict mortality in COPD. Eur. Respir. J. 2002; 20: 1147-1151.

264. Prescott E., Almdal T., Mikkelsen K.L. et al. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. Eur. Respir. J. 2002; 20: 539-544.

265. Schols A.M., Slangen J., Volovics L., Wouters E.F. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1791-1797.

266. Soriano J.B., Vestbo J., Pride N.B. et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur. Respir. J. 2002; 20: 819-825.

267. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.

268. Mannino D.M., Ford E.S., Redd S.C. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am. J. Med. 2003; 114: 758-762.

269. Cote C.G., Celli B.R. Pulmonary rehabilitation and the BODE index in COPD. Eur. Respir. J. 2005; 26: 630-636.

270. Imfeld S., Bloch K.E., Weder W., Russi E.W. The BODE index after lung volume reduction surgery correlates with survival. Chest 2006; 129: 873-878.

271. Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C. eds. Cost-effectiveness in health and medicine. 1-st ed. New York: Oxford University Press; 1996.

272. Drummond M.F., O'Brien B., Stoddart G.L., Torrance G.W., eds. Methods for the economic evaluation of health care programmes. 1-st ed. New York: Oxford University Press; 1997.

273. National Institute for Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2004.

274. Molken M.P., Van Doorslaer E.K., Rutten F.F. Economic appraisal of asthma and COPD care: a literature review 1980-1991. Soc. Sci. Med. 1992; 35: 161-175.

275. Ruchlin H.S., Dasbach E.J. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001; 19: 623-642.

276. Rutten-van Mölken M.P., Postma M.J., Joore M.A. et al.Current and future medical costs of asthma and chronic obstructive pulmonary disease in the Netherlands. Respir. Med. 1999; 93: 779-787.

277. Sullivan S.D., Ramsey S.D., Lee T.A. The economic burden of COPD. Chest 2000; 117 (suppl. 2): 5S-9S.

278. Strassels S.A., Smith D.H., Sullivan S.D., Mahajan P.S. The costs of treating COPD in the United States. Chest 2001; 119: 344-352.

279. Jansson S.A., Andersson F., Borg S. et al. Costs of COPD in Sweden according to disease severity. Chest 2002; 122: 1994-2002.

280. Miravitlles M., Murio C., Guerrero T., Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003; 123: 784-791.

281. Andersson F., Borg S., Jansson S.A. et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir. Med. 2002; 96: 700-708.

282. Oostenbrink J.B., Rutten-van M#ölken M.P. Resource use and risk factors in high-cost exacerbations of COPD. Respir. Med. 2004; 98: 883-891.

283. van den Berg B., Brouwer W.B., Koopmanschap M.A. Economic valuation of informal care. An overview of methods and applications. Eur. J. Hlth Econ. 2004; 5: 36-45.

284. Koopmanschap M.A. PRODISQ: a modular questionnaire on productivity and disease for economic evaluation studies. Expert. Rev. Pharmacoeconom. Outcomes Res. 2005; 5: 23-28.

285. Koopmanschap M.A., Rutten F.F., van Ineveld B.M., van Roijen L. The friction cost method for measuring indirect costs of disease. J. Hlth Econ. 1995; 14: 171-189.

286. Ramsey S.D., Patrick D.L., Albert R.K. et al.The cost-effectiveness of lung transplantation. A pilot study. University of Washington Medical Center Lung Transplant Study Group. Chest 1995; 108: 1594-1601.

287. Al M.J., Koopmanschap M.A., van Enckevort P.J. et al. Cost-effectiveness of lung transplantation in the Netherlands: a scenario analysis. Chest 1998; 113: 124-130.

288. Groen H., van der B.W., Koeter G.H., TenVergert E.M. Cost-effectiveness of lung transplantation in relation to type of end-stage pulmonary disease. Am. J. Transplant. 2004; 4: 1155-1162.

289. Ramsey S.D., Berry K., Etzioni R. et al. Cost-effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N. Engl. J. Med. 2003; 348: 2092-2102.

290. Anon J.M., Garcia de Lorenzo A., Zarazaga A. et al. Mechanical ventilation of patients on longterm oxygen therapy with acute exacerbations of chronic obstructive pulmonary disease: prognosis and cost-utility analysis. Intensive Care Med. 1999; 25: 452-457.

291. Goldstein R.S., Gort E.H., Guyatt G.H., Feeny D. Economic analysis of respiratory rehabilitation. Chest 1997; 112: 370-379.

292. Griffiths T.L., Phillips C.J., Davies S. et al. Cost-effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme. Thorax 2001; 56: 779-784.

293. Hoogendoorn M., Rutten-van Mölken M.P., Hoogenveen R.T. et al. A dynamic population model of disease progression in COPD. Eur. Respir. J. 2005; 26: 223-233.

294. van den B.G., Rutten-van Mölken M.P., Folgering H. et al. The economic effects of screening for obstructive airway disease: an economic analysis of the DIMCA program. Prev. Med. 2000; 30: 302-308.

295. Oostenbrink J.B., Rutten-van Mölken M.P., Al M.J. et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur. Respir. J. 2004; 23: 241-249.

296. van Hout B.A., Al M.J., Gordon G.S., Rutten F.F. Costs, effects and C / E-ratios alongside a clinical trial. Hlth Econ. 1994; 3: 309-319.

297. Briggs A., Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Hlth Econ. 1998; 7: 723-740.

298. Briggs A.H., Wonderling D.E., Mooney C.Z. Pulling cost-effectiveness analysis up by its bootstraps: a nonparametric approach to confidence interval estimation. Hlth Econ. 1997; 6: 327-340.

299. Langley P.C. The NICE reference case requirement: implications for drug manufacturers and health systems. Pharmacoeconomics 2004; 22: 267-271.

300. Fenwick E., Claxton K., Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Hlth Econ. 2001; 10: 779-787.

301. Sin D.D., Golmohammadi K., Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am. J. Med. 2004; 116: 325-331.

302. Borg S., Ericsson A., Wedzicha J. et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Hlth 2004; 7: 153-167.

303. Oostenbrink J.B., Rutten-van M#ölken M.P., Monz B.U., FitzGerald J.M. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Hlth 2005; 8: 32-46.

304. Spencer M., Briggs A.H., Grossman R.F., Rance L. Development of an economic model to assess the cost-effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23: 619-637.

305. Briggs A., Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397-409.

306. Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 709-721.

307. Miniati M., Filippi E., Falaschi F. et al. Radiologic evaluation of emphysema in patients with chronic obstructive pulmonary disease. Chest radiography versus high resolution computed tomography. Am. J. Respir. Crit. Care Med. 1995; 151: 1359-1367.

308. Kinsella M., Muller N.L., Staples C. et al. Hyperinflation in asthma and emphysema. Assessment by pulmonary function testing and computed tomography. Chest 1988; 94: 286-289.

309. Morrison N.J., Abboud R.T., Ramadan F. et al. Comparison of single breath carbon monoxide diffusing capacity and pressure-volume curves in detecting emphysema. Am. Rev. Respir. Dis. 1989; 139: 1179-1187.

310. Parr D.G., Stoel B.C., Stolk J., Stockley R.A. Validation of computed tomographic lung densitometry for monitoring emphysema in a1-antitrypsin deficiency. Thorax 2006; 61: 485-490.

311. Biernacki W., Ryan M., MacNee W., Flenley D.C. Can the quantitative CT scan detect progression of emphysema? Am. Rev. Respir. Dis. 1989; 131: A120.

312. Dirksen A., Dijkman J.H., Madsen F. et al. A randomized clinical trial of a1-antitrypsin augmentation therapy. Am. J. Respir. Crit. Care Med. 1999; 160: 1468-1472.

313. Dowson L.J., Guest P.J., Stockley R.A. Longitudinal changes in physiological, radiological, and health status measurements in a1-antitrypsin deficiency and factors associated with decline. Am. J. Respir. Crit. Care Med. 2001; 164: 1805-1809.

314. Soejima K., Yamaguchi K., Kohda E. et al. Longitudinal follow-up study of smoking-induced lung density changes by high-resolution computed tomography. Am. J. Respir. Crit. Care Med. 2000; 161: 1264-1273.

315. Nakano Y., Muro S., Sakai H. et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am. J. Respir. Crit. Care Med. 2000; 162: 1102-1108.

316. Orlandi I., Moroni C., Camiciottoli G. et al. Chronic obstructive pulmonary disease: thin-section CT measurement of airway wall thickness and lung attenuation. Radiology 2005; 234: 604-610.

317. Nakano Y., Muller N.L., King G.G. et al. Quantitative assessment of airway remodeling using high-resolution CT. Chest 2002; 122 (suppl. 6): 271S-275S.

318. O'Donnell R.A., Peebles C., Ward J.A. et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 2004; 59: 837-842.

319. Hayhurst M.D., MacNee W., Flenley D.C. et al. Diagnosis of pulmonary emphysema by computerised tomography. Lancet 1984; 2: 320-322.

320. Guenard H., Diallo M.H., Laurent F., Vergeret J. Lung density and lung mass in emphysema. Chest 1992; 102: 198-203.

321. Haraguchi M., Shimura S., Hida W., Shirato K. Pulmonary function and regional distribution of emphysema as determined by high-resolution computed tomography. Respiration 1998; 65: 125-129.

322. Heremans A., Verschakelen J.A., Van Fraeyenhoven L., Demedts M. Measurement of lung density by means of quantitative CT scanning. A study of correlations with pulmonary function tests. Chest 1992; 102: 805-811.

323. Hartley P.G., Galvin J.R., Hunninghake G.W. et al. Highresolution CT-derived measures of lung density are valid indexes of interstitial lung disease. J. Appl. Physiol. 1994; 76: 271-277.

324. Rienmuller R.K., Behr J., Kalender W.A. et al. Standardized quantitative high resolution CT in lung diseases. J. Comput. Assist. Tomogr. 1991; 15: 742-749.

325. Gould G.A., MacNee W., McLean A. et al. CT measurements of lung density in life can quantitate distal airspace enlargement - an essential defining feature of human emphysema. Am. Rev. Respir. Dis. 1988; 137: 380-392.

326. Gould G.A., Redpath A.T., Ryan M. et al. Lung CT density correlates with measurements of airflow limitation and the diffusing capacity. Eur. Respir. J. 1991; 4: 141-146.

327. Dirksen A., Friis M., Olesen K.P. et al. Progress of emphysema in severe a1-antitrypsin deficiency as assessed by annual CT. Acta Radiol. 1997; 38: 826-832.

328. Bankier A.A., De Maertelaer V., Keyzer C., Gevenois P.A. Pulmonary emphysema: subjective visual grading versus objective quantification with macroscopic morphometry and thin-section CT densitometry. Radiology 1999; 211: 851-858.

329. Gevenois P.A., De Maertelaer V., De Vuyst P. et al. Comparison of computed density and macroscopic morphometry in pulmonary emphysema. Am. J. Respir. Crit. Care Med. 1995; 152: 653-657.

330. Gevenois P.A, De Vuyst P., Sy M. et al. Pulmonary emphysema: quantitative CT during expiration. Radiology 1996; 199: 825-829.

331. Gevenois P.A., De Vuyst P., De Maertelaer V. et al. Comparison of computed density and microscopic morphometry in pulmonary emphysema. Am. J. Respir. Crit. Care Med. 1996; 154: 187-192.

332. Muller N.L., Staples C.A., Miller R.R., Abboud R.T. ''Density mask''. An objective method to quantitate emphysema using computed tomography. Chest 1988; 94: 782-787.

333. Dowson L.J., Guest P.J., Hill S.L. et al. High-resolution computed tomography scanning in a1-antitrypsin deficiency: relationship to lung function and health status. Eur. Respir. J. 2001; 17: 1097-1104.

334. Parr D.G., Stoel B.C., Stolk J., Stockley R.A. Pattern of emphysema distribution in a1-antitrypsin deficiency influences lung function impairment. Am. J. Respir. Crit. Care Med. 2004; 170: 1172-1178.

335. Kinsella M., Muller N.L., Abboud R.T. et al. Quantitation of emphysema by computed tomography using a ''density mask'' program and correlation with pulmonary function tests. Chest 1990; 97: 315-321.

336. Park K.J., Bergin C.J., Clausen J.L. Quantitation of emphysema with three-dimensional CT densitometry: comparison with two-dimensional analysis, visual emphysema scores, and pulmonary function test results. Radiology 1999; 211: 541-547.

337. Nakano Y., Wong J.C., de Jong P.A. et al. The prediction of small airway dimensions using computed tomography. Am. J. Respir. Crit. Care Med. 2005; 171: 142-146.

338. King G.G., Muller N.L., Whittall K.P. et al. An analysis algorhythm for measuring airway lumen and wall areas from high-resolution computed tomographic data. Am. J. Respir. Crit. Care Med. 2000; 161: 574-580.

339. Berger P., Perot V., Desbarats P. et al. Airway wall thickness in cigarette smokers: quantitative thin-section CT assessment. Radiology 2005; 235: 1055-1064.

340. Matsuoka S., Kurihara Y., Nakajima Y. et al. Serial change in airway lumen and wall thickness at thin-section CT in asymptomatic subjects. Radiology 2005; 234: 595-603.

341. Brillet P.Y., Fetita C.I., Beigelman-Aubry C. et al. Quantification of bronchial dimensions at MDCT using dedicated software. Eur. Radiol. 2007; 17: 1483-1489.

342. Kemerink G.J., Lamers R.J., Thelissen G.R., Van Engelshoven J.M. CT densitometry of the lungs: scanner performance. J. Comput. Assist. Tomogr. 1996; 20: 24-33.

343. Parr D.G., Stoel B.C., Stolk J. et al. Influence of calibration on densitometric studies of emphysema progression using computed tomography. Am. J. Respir. Crit. Care Med. 2004; 170: 883-890.

344. Kemerink G.J., Lamers R.J., Thelissen G.R., Van Engelshoven J.M. The nonlinear partial volume effect and computed tomography densitometry of foam and lung. Med. Phys. 1995; 22: 1445-1450.

345. Van Dyk J., Keane T.J., Rider W.D. Lung density as measured by computerized tomography: implications for radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1982; 8: 1363-1372.

346. Wegener O.H., Koeppe P., Oeser H. Measurement of lung density by computed tomography. J. Comput. Assist. Tomogr. 1978; 2: 263-273.

347. Kalender W.A., Rienmuller R., Seissler W. et al. Measurement of pulmonary parenchymal attenuation: use of spirometric gating with quantitative CT. Radiology 1990; 175: 265-268.

348. Gierada D.S., Yusen R.D., Pilgram T.K. et al. Repeatability of quantitative CT indexes of emphysema in patients evaluated for lung volume reduction surgery. Radiology 2001; 220: 448-454.

349. Hoffman E.A., McLennan G. Assessment of the pulmonary structure-function relationship and clinical outcomes measures: quantitative volumetric CT of the lung. Acad. Radiol. 1997; 4: 758-776.

350. Shaker S.B., Dirksen A., Laursen L. et al. Volume adjustment of lung density by computed tomography scans in patients with emphysema. Acta Radiol. 2004; 45: 417-423.

351. Stolk J., Dirksen A., van der Lugt A.A. et al. Repeatability of lung density measurements with low-dose computed tomography in subjects with a1-antitrypsin deficiencyassociated emphysema. Invest. Radiol. 2001; 36: 648-651.

352. Lamers R.J., Kemerink G.J., Drent M., Van Engelshoven J.M. Reproducibility of spirometrically controlled CT lung densitometry in a clinical setting. Eur. Respir. J. 1998; 11: 942-945.

353. Moroni C., Mascalchi M., Camiciottoli G. et al. Comparison of spirometric-gated and -ungated HRCT in COPD. J. Comput. Assist. Tomogr. 2003; 27: 375-379.

354. Newell J.D., Hogg J.C., Snider G.L. Report of a workshop: quantitative computed tomography scanning in longitudinal studies of emphysema. Eur. Respir. J. 2004; 23: 769-775.

355. Robinson P.J., Kreel L. Pulmonary tissue attenuation with computed tomography: comparison of inspiration and expiration scans. J. Comput. Assist. Tomogr. 1979; 3: 740-748.

356. Siegelman S. Pulmonary system: Practical approaches to pulmonary diagnosis. New York: Grune and Stratton; 1979.